Eli Lilly and Company (SNSE:LLYCL)
Chile · Delayed Price · Currency is CLP | Market Cap | 876.77T +45.4% |
| Revenue (ttm) | 67.18T +47.4% |
| Net Income | 23.50T +127.6% |
| EPS | 26,174.64 +129.1% |
| Shares Out | n/a |
| PE Ratio | 37.31 |
| Forward PE | 29.62 |
| Dividend | 5,861.71 (0.58%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 4 |
| Open | 972,450 |
| Previous Close | 1,007,933 |
| Day's Range | 972,450 - 984,500 |
| 52-Week Range | 608,400 - 1,034,500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients
We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.
Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
That means millions more Americans may get access to Lilly's new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.
Eli Lilly and Company Transcript: Bernstein 42nd Annual Strategic Decisions Conference
The event highlighted a differentiated, long-term R&D strategy, rapid drug development, and a robust pipeline in obesity, neuroscience, and genetic medicine. AI and proprietary data are key competitive advantages, while early-stage acquisitions and direct-to-patient models support future growth.
Lilly to present new Foundayo, Mounjaro and retatrutide data at ADA meeting
Eli Lilly (LLY) will present new data across its cardiometabolic portfolio at the American Diabetes Association’s 86th Scientific Sessions taking place June 5-8 in New Orleans. “Together, these findin...
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefi...
Eli Lilly Stock (LLY) Jumps 5% as CVS Health Covers Its Weight-Loss Drugs
The move is seen as a major win for the pharma giant.
Eli Lilly reports PBMs to cover full obesity medicine portfolio
Eli Lilly (LLY) announced all three of the nation’s largest pharmacy benefit managers, or PBMs, will cover Lilly’s full obesity medicine portfolio. This significantly expands the number of Americans w...
CVS brings back coverage for Lilly's obesity drug Zepbound
CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage.
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS Health said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans. The move supports Lilly's efforts...
Foundayo and Zepbound now covered for millions of Americans
CVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicine INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- El...
4 Stocks To Buy Before The S&P 500 Hits 8,000
Robert Schein, Chief Investment Officer of Blanke Schein Wealth Management says the market's rally still has room to run - and breaks down the four stocks he thinks are positioned to win before the S&...
Eli Lilly Stock (LLY) Gets a Price Target Boost as Weight-Loss Drug Sales Accelerate
Indications are that the new weight-loss pill is selling well.
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
INDIANAPOLIS, May 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vi...
Healthy Returns: Eli Lilly makes a new push into vaccines – here's what to know
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine
Eli Lilly agreed to acquire Bothell, Wash.
Goldman Sachs reveals its top non-AI stocks
The artificial intelligence (AI) boom continues to set the direction for global financial markets in 2026, but Goldman Sachs strategists argue that opportunities exist outside this tech narrative as w...
Midday Fly: Eli Lilly to acquire vaccine makers, BP chair removed
The major averages were mixed near noon as markets react to reports of potential progress in U.S.–Iran talks aimed at ending the conflict, with sentiment supported by President Trump’s comments…
Eli Lilly Stock (LLY) Climbs Higher on News of $4 Billion Acquisition Spree
The company has been on a buying spree lately.
Lilly Gets Back Into the Vaccine Business With New Deals
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity ...
Morning Movers: Eli Lilly gets boost amid plans for nearly $4B in vaccine deals
Stock futures rose Tuesday as markets reacted to reports of potential progress in U.S.–Iran talks aimed at ending the conflict, with sentiment supported by President Trump’s comments that negotiations...
Video: Eli Lilly rises after vaccine acquisitions
The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will be moving and why. Published…
Eli Lilly price target raised to $1,251 from $1,133 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,251 from $1,133 and keeps a Buy rating on the shares. The firm expects Lilly’s overall revenue and profit…
Lilly Agrees to Buy Trio of Vaccine Developers
The weight-loss drug market leader is renewing a focus on infectious-disease prevention.
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly's effort to expand into infectious disease research and development. Shares edged higher in premarket trading on the news.